Navigation Links
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Date:6/24/2008

Partners Expect Program to Advance to the Clinic Within a Year; Studies

Generate Milestone Payment to Micromet

BETHESDA, Md., and ZURICH, Switzerland, June 24 /PRNewswire/ -- Micromet, Inc. (Nasdaq: MITI) and Nycomed today announced the initiation of formal preclinical safety studies for the anti-GM-CSF human antibody MT203. Micromet received $775,000 (500,000 euros) from Nycomed for the achievement of this milestone.

Under a 2007 agreement between the two companies, Micromet and Nycomed develop MT203, a fully human anti-GM-CSF antibody that may be useful for the treatment of various inflammatory and autoimmune diseases. Preclinical studies support MT203's development for the treatment of rheumatoid arthritis and several other indications, including multiple sclerosis, psoriasis, asthma and chronic obstructive pulmonary disease.

"Data on MT203 remain encouraging and we are pleased to reach this important developmental milestone," said Jens Hennecke, Micromet's Vice President of Business Development. "The MT203 program is well on track and we are looking forward to advancing it into the clinic within a year."

"Within our partnership, Micromet has continued to deliver encouraging data on MT203 related to the treatment of inflammatory and autoimmune diseases," said Anders Ullman, Nycomed's Executive Vice President Research and Development. "MT203 represents an important asset in our early stage pipeline."

About Nycomed (http://www.nycomed.com)

Nycomed is a privately owned pharmaceutical company that provides medicines for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets. It
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...., Nov. 25 The FDA granted traditi...lets, a non-nucleoside reverse transcriptase inhib...ally indicated for use in treatment-experienced ad...IV-1 strains resistant to an NNRTI and other antir...is based on 48-week data from two Phase 3 studies ...
(Date:11/25/2009)... Md., Nov. 25 Remedium ...cream-like foam that stops severe bleeding, won fi...ty Idea category of the Global Security Challenge ...cted from more than 100 entries from around the wo...e GSC Security Summit conference held at the Londo...
(Date:11/25/2009)... N.J., Nov. 25 Regado Biosciences,...of antithrombotic aptamers with active control age...ident, will be presenting at the Piper Jaffray 21s...lace Hotel in New York City. Dr. Mazzo,s presenta...ember 1 and will include an overview of the Compan...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2The Tile Doctor Launches Inaugural Product Line 14086 1The Tile Doctor Launches Inaugural Product Line 14086 2The Tile Doctor Launches Inaugural Product Line 14086 3Free Screenings During Prostate Cancer Awareness Week 57323 1Free Screenings During Prostate Cancer Awareness Week 57323 2Free Screenings During Prostate Cancer Awareness Week 57323 3Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference 14084 1Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference 14084 2
...s Enrolled in Clinical Trial to Assess Survival of...herapies for Unresectable Hepatocellular Carcinoma... Oncology, Inc. (LSO) today announced the completi...l of Light Infusion Therapy(TM) (Litx(TM)) as a tr...(HCC), also known as hepatoma or primary liver can...
... Pancreatic Cancer Awareness Month , , Oak Br...rointestinal Endoscopy (ASGE) and the Pancreatic C...to raise awareness about pancreatic cancer, educat...hat are available for them. , , Pancreatic ca...in the U.S. In 2008, an estimated 37,680 Americans...
Other Medicine Technology:Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 2ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 4ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 5ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 6
(Date:11/27/2009)...v. 27 Allrecipes.com , the worl...g traffic numbers, with more than 2.8 million visi...r picture of what was served on the biggest food h...in 2009 weighed in at 2,225 calories per serving, ...ding to the Allrecipes site, Sweet Potato Pie I ...
(Date:11/27/2009)...nufacturers who use medical load cells at the hear... by bringing in technology partner Flintec early i...tive medical manufacturers are calling in Flintec ...ojects, ensuring that progress will not be constra...utdated technology. , (PR...
(Date:11/26/2009)... The diabetes population in the Uni...rs and annual medical spending on the disease is p... today, according to a study published in the Dece...ging Diabetes ® Program (NCDP), a program of ...from the University of Chicago. ,, According to...
(Date:11/26/2009)... lead to strains or worse , , THURSDAY, ...rong with stuffing your turkey full to bursting, b...ur suitcase as you pack for holiday trips. , Mo... hospital emergency rooms, doctors, offices, clini...d injuries, such as muscle strains, pulls and tear...
(Date:11/26/2009)... of the Live Life Again Center, a practice offerin...wing number of physicians who are taking advantag...th individuals who are interested in surgical weig... is utilizing Facebook to share before-and-after p...community. , Dallas, TX (...
Breaking Medicine News(10 mins):Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3
...dical, Inc. (OTC Bulletin Board: AEMD) confirmed t...te to treat the H1N1 Swine flu virus. The Hemopur...at assists the immune response in combating infect...ier(R) has previously proven effective in capturin...
... Access to Nursing Home, Assisted Living, Home Car...Zip Code Statewide , , RICHMOND, Va., April 30 ... a rate outpacing inflation, putting significant f... has led to a decline in home values and investmen...
...$0.42 - , , - Annual Guidance Narrowed to $2.05 t...nce Call Scheduled for 9 a.m. Today - , , LIONVI...Inc. (NYSE: WST ) today announced its results fo... March 31, ...
...sents First True Yellow Laser with CW-Pulse(TM) an...f., April 30 IRIDEX Corporation, (Nasdaq: IRIX ... customers of the IQ 577 laser systems. The IQ 577...tinopathy, age-related macular degeneration and gl...
...o $24.9 billion , , - GAAP earnings from continui...nd decrease 10 percent to $350 million on a non-GA...om continuing operations decline 15 percent to $0....improve the safety and productivity of health care...
...ncome , , POWAY, Calif., April 30 Digirad Corpor...ad of internal schedules on its 2009 goal of gener...low. Net income was $44,000 for the first quarter...rter. We previously communicated our 2009 goals a...
Other Medicine News:Health News:Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus 2Health News:Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus 3Health News:Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus 4Health News:Growth in Indiana Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Indiana Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Indiana Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:West Announces First Quarter 2009 Results 2Health News:West Announces First Quarter 2009 Results 3Health News:West Announces First Quarter 2009 Results 4Health News:West Announces First Quarter 2009 Results 5Health News:West Announces First Quarter 2009 Results 6Health News:West Announces First Quarter 2009 Results 7Health News:West Announces First Quarter 2009 Results 8Health News:West Announces First Quarter 2009 Results 9Health News:West Announces First Quarter 2009 Results 10Health News:West Announces First Quarter 2009 Results 11Health News:West Announces First Quarter 2009 Results 12Health News:West Announces First Quarter 2009 Results 13Health News:West Announces First Quarter 2009 Results 14Health News:West Announces First Quarter 2009 Results 15Health News:West Announces First Quarter 2009 Results 16Health News:West Announces First Quarter 2009 Results 17Health News:West Announces First Quarter 2009 Results 18Health News:IRIDEX Announces Shipment of New IQ 577(TM) Laser Systems 2Health News:Cardinal Health Reports Third Quarter Results 2Health News:Cardinal Health Reports Third Quarter Results 3Health News:Cardinal Health Reports Third Quarter Results 4Health News:Cardinal Health Reports Third Quarter Results 5Health News:Cardinal Health Reports Third Quarter Results 6Health News:Cardinal Health Reports Third Quarter Results 7Health News:Cardinal Health Reports Third Quarter Results 8Health News:Cardinal Health Reports Third Quarter Results 9Health News:Cardinal Health Reports Third Quarter Results 10Health News:Cardinal Health Reports Third Quarter Results 11Health News:Cardinal Health Reports Third Quarter Results 12
Freedom Clear® LS External Catheters
Natural Male External Catheters
...Medical® clear, all-silicone Foley catheters e...oley catheter designs. As an inert, toxin-free ela...endable Foley catheter. Unlike silicone-coated lat...ers will not leach chemicals or water-soluble prot...
...lled-release nitrofurazone Foley catheter, RELEASE...eter is the first and only Foley that works as a d... RELEASE-NF catheter delivers the drug nitrofurazo... of the urethral tract. Unlike coated catheters, w...
Medicine Products: